Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanicemine for Hyperarousal in PTSD
NCT03166501Phase 1Completed
- Sponsor
- Baylor College of Medicine
- Start
- Sep 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing Lanicemine with Placebo (2 arms). Primary endpoint: Anxiety Potentiated Startle response at 5 days. Started Sep 2018; status: completed.
02
Drugs
lanicemine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03166501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03166501.